Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Cancer Res. 2019 May 2;79(13):3466–3478. doi: 10.1158/0008-5472.CAN-18-3014

Table 1.

Cox regression models of DFS

Univariate Multivariate
Variable Hazard Ratio (95% Confidence Interval) P-value Hazard Ratio (95% Confidence Interval) P-value
Training Set Immune Activation Score (log10 transformed) 0.1430 (0.03683– 0.5555) 0.00496* 0.1688 (0.04039–0.7054) 0.014758*
Stage at Diagnosis 2.1227 (1.439– 3.131) 0.000147* 2.0310 (1.33617–3.0871) 0.000911*
Age at Diagnosis 1.006 (0.9661– 1.048) 0.765 1.0363 (0.99081–1.0840) 0.119459
Received Chemotherapy 0.4879 (0.1752– 1.359) 0.17 0.4660 (0.14512–1.4965) 0.199589
Validation Cohort Immune Activation Score (log10 transformed) 0.2111 (0.06075–0.7335) 0.01440* 0.1939 (0.05451–0.6896) 0.011280*
Stage at Diagnosis 1.628 (1.204–2.201) 0.00154* 1.6363 (1.18309–2.2632) 0.002920*
Age at Diagnosis 1.013 (0.9812–1.045) 0.43200 1.0198(0.96152–1.0605) 0.696870
Received Chemotherapy 0.6166 (0.1986–1.915) 0.40300 0.7696 (0.14986–3.9519) 0.753700
*

significant P-values